Healthcare (SH:603313)2019-10-29 16:00Financial Performance - Net profit attributable to shareholders rose by 135.89% to CNY 260,476,255.50 for the period from January to September[17]. - Operating revenue grew by 25.40% to CNY 2,638,780,331.72 year-on-year[17]. - Basic earnings per share increased by 78.26% to CNY 0.82[17]. - The company reported a significant increase in net profit after deducting non-recurring gains and losses, which rose by 99.13% to CNY 269,279,184.28[17]. - Total operating revenue for Q3 2019 reached CNY 1,058,578,748.00, a 28.9% increase from CNY 821,379,506.04 in Q3 2018[47]. - Net profit for Q3 2019 was CNY 119,047,480.53, compared to CNY 74,712,809.61 in Q3 2018, reflecting a 59.0% increase[51]. - The company reported a total comprehensive income of CNY 118,599,397.66 for Q3 2019, compared to CNY 72,355,871.40 in Q3 2018[53]. - The company reported a total profit of CNY 92.98 million in Q3 2019, down 4.0% from CNY 97.11 million in Q3 2018[59]. Assets and Liabilities - Total assets increased by 20.63% to CNY 4,072,376,847.88 compared to the end of the previous year[17]. - Total liabilities increased to ¥1,915,998,904.37, up from ¥1,490,721,735.56, representing a growth of approximately 28.5% year-over-year[38]. - Current assets totaled RMB 2,215,070,444.78, compared to RMB 2,102,399,489.48 in the previous year[32]. - The total assets reached ¥3,688,415,727.49, compared to ¥3,235,094,771.70, showing an increase of approximately 14.0%[42]. - The company’s total liabilities and shareholders' equity increased to CNY 3,688,415,727.49 from CNY 3,235,094,771.70[47]. - Total liabilities reached approximately $1.49 billion, with non-current liabilities accounting for $378.46 million[75]. - Shareholders' equity totaled approximately $1.89 billion, with retained earnings at $486.08 million[75]. Cash Flow - Net cash flow from operating activities surged by 240.10% to CNY 146,615,248.99 for the first nine months[17]. - Cash flow from operating activities for the first three quarters of 2019 was CNY 2.82 billion, compared to CNY 2.32 billion in the same period of 2018, reflecting a growth of 21.5%[61]. - The company reported a net cash flow from financing activities of 200,273,443.63 RMB, a decrease from 375,765,276.95 RMB, suggesting a shift in financing strategy[64]. - Cash paid for debt repayment rose by 70.02% to RMB 670,707,921.14, primarily due to loan repayments[28]. - The cash and cash equivalents at the end of the period were 516,624,003.07 RMB, down from 880,577,725.03 RMB, reflecting a net decrease in cash reserves[68]. Shareholder Information - The total number of shareholders reached 20,863 by the end of the reporting period[22]. - The largest shareholder, Ni Zhanggen, holds 62.19% of the shares, with 200,401,319 shares[22]. Investments and Expenses - Cash paid for the purchase of fixed assets and other long-term assets increased by 161.79% to RMB 544,277,364.30, reflecting increased long-term asset investments[28]. - Research and development expenses for Q3 2019 totaled CNY 28,756,611.01, an increase from CNY 24,781,103.38 in Q3 2018[47]. - Management expenses rose by 46.31% to RMB 157,727,311.81, mainly due to new company expenses and increased employee compensation[28]. - The company’s investment income showed a loss of CNY 377,731.38 in Q3 2019, compared to a gain of CNY 1,857,789.00 in Q3 2018[51]. Other Financial Metrics - The weighted average return on equity improved by 5.55 percentage points to 12.51%[17]. - The company’s gross profit margin improved, with gross profit for Q3 2019 at CNY 186,323,326.25, compared to CNY 104,929,561.99 in Q3 2018[47]. - The company has a goodwill amounting to approximately $60.41 million[72].